The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.< ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for neovascular AMD, diabetic macular edema, and other ocular conditions, ...

Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from Health Canada for Yesafili (aflibercept), a biosimilar to Eylea, marking the first such approval for an Eylea biosimilar in the ...

Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Bayer’s Eylea, concluded ...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ...

Alvotech and Advanz Pharma announce positive EMA opinion for AVT06, a biosimilar to Eylea®, advancing access for eye disorder treatments in Europe.

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

Biotech seeks to stop Kirkland from representing rival in Eylea dispute Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to ...